Arcturus Therapeutics Holdings ARCT
NASDAQ ARCT
$9.31 -0.08 (-0.85%)
At close: Nov 11, 2026 · 4:00 PM EST

Arcturus Therapeutics Holdings (ARCT) Gains from Sales and Divestitures (2026)

Updated

Arcturus Therapeutics Holdings (ARCT) recorded Gains from Sales and Divestitures of $18,000 in Q2 2026, down 47.1% from the prior quarter.

Analysis

Arcturus Therapeutics Holdings (ARCT) Gains from Sales and Divestitures (2026) Analysis & Trends

On a TTM basis, Arcturus Therapeutics Holdings' Gains from Sales and Divestitures came in at $52,000 as of Jun 30, 2026.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Arcturus Therapeutics Holdings 267.25 Mn -551.34 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 8,000.00
Jun 30, 2026 38,000.00
Mar 31, 2026 34,000.00
API Access

Arcturus Therapeutics Holdings Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=ARCT&period=max&api_key=YOUR_API_KEY